OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Siddiqui on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

December 14th 2021

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Jain on the Need to Enroll Heterogenous Populations to Clinical Trials in CRC

December 14th 2021

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Dr. McKinney on the Emergence of CAR T-Cell Therapy in Relapsed/Refractory MCL

December 14th 2021

Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Burke on POLARIX Data Examining a Polatuzumab Vedotin–Based Regimen in Newly Diagnosed DLBCL

December 14th 2021

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma

December 14th 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Heyman on Future Therapeutic Directions in MCL

December 14th 2021

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

December 14th 2021

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

December 14th 2021

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

December 13th 2021

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Ghia on the Results From the 2-Year Follow-Up of the CAPTIVATE Study in CLL

December 13th 2021

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

December 12th 2021

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

December 12th 2021

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin Lymphoma

December 11th 2021

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

December 11th 2021

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. McKinney on Emerging Therapeutic Strategies in MCL

December 10th 2021

Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses emerging therapeutic strategies in mantle cell lymphoma (MCL).

Dr. Randall on the Evolution of Limb Salvage Technologies in Bone Sarcomas

December 10th 2021

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

December 10th 2021

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

December 10th 2021

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Kruse on the Results of a Study Comparing Outcomes in Pleomorphic Vs Non-Pleomorphic Invasive Lobular Carcinoma

December 10th 2021

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Dr. Heyman on ROR1-Targeted Approaches in Relapsed/Refractory MCL

December 9th 2021

Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma.